Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

[1]  À. Rovira,et al.  Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes , 2013, Multiple sclerosis.

[2]  J. Menzin,et al.  Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis , 2013, Journal of managed care pharmacy : JMCP.

[3]  P. Calabresi,et al.  PEGylation of Interferon-β-1a , 2012, CNS Drugs.

[4]  I. Nestorov,et al.  A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology , 2012, Journal of clinical pharmacology.

[5]  Martin Müller,et al.  The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study , 2011, BMC neurology.

[6]  S. Nikfar,et al.  A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. , 2010, Clinical therapeutics.

[7]  F. Patti.  Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence , 2010, Patient preference and adherence.

[8]  C. Pozzilli,et al.  One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis , 2009, European journal of neurology.

[9]  A. Lugaresi.  Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? , 2009, Expert opinion on drug delivery.

[10]  J. Fischer,et al.  Quality of life in 1000 patients with early relapsing–remitting multiple sclerosis , 2009, European journal of neurology.

[11]  C. Won,et al.  PEG-modified biopharmaceuticals , 2009 .

[12]  Chee-Youb Won,et al.  PEG-modified biopharmaceuticals. , 2009, Expert opinion on drug delivery.

[13]  V. Gaberc-Porekar,et al.  Obstacles and pitfalls in the PEGylation of therapeutic proteins. , 2008, Current opinion in drug discovery & development.

[14]  A. Thompson,et al.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.

[15]  Sanjay K. Jain,et al.  PEGylation: an approach for drug delivery. A review. , 2008, Critical reviews in therapeutic drug carrier systems.

[16]  G. Foster,et al.  Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a , 2007, International journal of nanomedicine.

[17]  E. Frohman,et al.  Multiple sclerosis--the plaque and its pathogenesis. , 2006, The New England journal of medicine.

[18]  A. Whitty,et al.  N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. , 2006, Bioconjugate chemistry.

[19]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[20]  R. Rudick,et al.  Defining interferon β response status in multiple sclerosis patients , 2004 .

[21]  R. Rudick,et al.  Defining interferon beta response status in multiple sclerosis patients. , 2004, Annals of neurology.

[22]  F. Lublin,et al.  Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.

[23]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[24]  A. Członkowska,et al.  [Axonal degeneration in the pathogenesis of multiple sclerosis]. , 2002, Neurologia i neurochirurgia polska.

[25]  B. Trapp,et al.  Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences , 2001, Current opinion in neurology.

[26]  G. Ebers.  Preventing multiple sclerosis? , 2001, The Lancet.

[27]  D. Goodkin,et al.  Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-inject , 2001, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[28]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[29]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[30]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[31]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[32]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[33]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[34]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.